Abstract P6-10-19: Screening of GPCR-targeting drugs for repositioning in breast cancer

Noor Mazin Abdulkareem(The University of Texas MD Anderson Cancer Center), Meghana V. Trivedi(University of Houston), Lisa Trinh(University of Houston), Reid T. Powell(Texas A&M Health Science Center), Mary Sobieski(Texas A&M University), Hala Y. Abdelnasser(University of Houston), Nghi Nguyen(University of Houston), S. Yande(University of Houston), Alexis Ruiz(University of Houston), Clifford Stephan(Texas A&M Health Science Center), Soumya Chikermane(University of Houston), Raksha R. Bhat(University of Houston), Michael L. Johnson(University of Houston), Camille S. Johnson(University of Houston)
Cancer Research
March 1, 2023
10.1158/1538-7445.sabcs22-p6-10-19
Cited by 0

Related Papers

Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II
|Value in Health|2009|309
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185